AN2 Therapeutics, Inc. - Common Stock (NQ:ANTX)

3.915 +0.145 (+3.85%)

Streaming Delayed Price Updated: 11:39 AM EDT, Mar 25, 2026 Add to My Watchlist

Price and Volume

Volume	307,759
Open	3.830
Bid (Size)	3.850 (100)
Ask (Size)	3.980 (100)
Prev. Close	3.770
Today's Range	3.470 - 4.010
52wk Range	1.000 - 6.910
Shares Outstanding	21,928,452
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

March 17, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

Top stock movements in today's session. ↗

March 09, 2026

Via Chartmill

Performance

YTD	+252.7%	+252.7%
1 Month	+272.9%	+272.9%
3 Month	+249.6%	+249.6%
6 Month	+203.5%	+203.5%
1 Year	+159.3%	+159.3%

More News

AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? ↗

March 09, 2026

Via Benzinga

ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!

March 09, 2026

Via AB Newswire

ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally? ↗

March 09, 2026

Via Stocktwits

In today's session, these stocks are experiencing unusual volume. ↗

March 09, 2026

Via Chartmill

Monday's session: top gainers and losers ↗

March 09, 2026

Via Chartmill

AN2 Therapeutics Announces $40 Million Private Placement Financing

March 09, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

Here are the top movers in Friday's session. ↗

March 06, 2026

Via Chartmill

Which stocks are moving on Friday? ↗

March 06, 2026

Via Chartmill

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

March 03, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

February 17, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

January 12, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

November 12, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

November 10, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

November 06, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 23, 2025

Via Benzinga

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

August 12, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

August 12, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

July 23, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

June 30, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

May 29, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

May 13, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 01, 2025

Via Benzinga

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

May 01, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is AN2 Therapeutics, Inc. - Common Stock publicly traded?

Yes, AN2 Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does AN2 Therapeutics, Inc. - Common Stock trade on?

AN2 Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for AN2 Therapeutics, Inc. - Common Stock?

The ticker symbol for AN2 Therapeutics, Inc. - Common Stock is ANTX on the Nasdaq Stock Market

What is the current price of AN2 Therapeutics, Inc. - Common Stock?

The current price of AN2 Therapeutics, Inc. - Common Stock is 3.915

When was AN2 Therapeutics, Inc. - Common Stock last traded?

The last trade of AN2 Therapeutics, Inc. - Common Stock was at 03/25/26 11:39 AM ET

What is the market capitalization of AN2 Therapeutics, Inc. - Common Stock?

The market capitalization of AN2 Therapeutics, Inc. - Common Stock is 85.85M

How many shares of AN2 Therapeutics, Inc. - Common Stock are outstanding?

AN2 Therapeutics, Inc. - Common Stock has 86M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.